Cutler Group LP Assembly Biosciences, Inc. Call Options Transaction History

Cutler Group LP

13 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2021 Jul 19, 2021	SELL	$3.8 - $4.56 $1,900 - $2,280	-500 Reduced 83.33%	100 $0
Q4 2020 Jan 21, 2021	SELL	$4.87 - $17.29 $487 - $1,729	-100 Reduced 14.29%	600 $0
Q3 2020 Oct 27, 2020	BUY	$15.08 - $27.04 $7,540 - $13,520	500 Added 250.0%	700 $0
Q2 2020 Jul 22, 2020	SELL	$14.57 - $23.96 $13,113 - $21,564	-900 Reduced 81.82%	200 $0
Q1 2020 May 07, 2020	SELL	$10.27 - $21.23 $4,108 - $8,492	-400 Reduced 26.67%	1,100 $0

Q4 2019 Feb 06, 2020	BUY	$8.36 - $23.81 $11,704 - $33,334	1,400 Added 1400.0%	1,500 $3,000
Q3 2019 Oct 28, 2019	SELL	$9.83 - $14.82 $10,813 - $16,302	-1,100 Reduced 91.67%	100 $0
Q2 2019 Aug 09, 2019	BUY	$12.9 - $20.8 $14,190 - $22,880	1,100 Added 1100.0%	1,200 $0
Q4 2018 Feb 05, 2019	SELL	$19.05 - $36.45 $41,910 - $80,190	-2,200 Reduced 95.65%	100 $0
Q3 2018 Nov 07, 2018	BUY	$34.41 - $44.23 $27,527 - $35,384	800 Added 53.33%	2,300 $5,000
Q2 2018 Aug 10, 2018	BUY	$39.21 - $50.29 $19,605 - $25,145	500 Added 50.0%	1,500 $5,000
Q1 2018 May 11, 2018	SELL	$41.7 - $64.16 $66,720 - $102,656	-1,600 Reduced 61.54%	1,000 $1,000
Q4 2017 Jan 17, 2018	BUY	$28.58 - $49.91 $74,308 - $129,765	2,600	2,600 $41,000

16.3K

Ticker ASMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,436,900
Market Cap $667M
Description
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also deve...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.